EACS2023: 799 HIV molecular epidemiology and resistance profiles in HIV-infected refugees from Ukraine in Hamburg, Germany A. Koval , H. Matthews , S. Polywka , M. Böhm , M. Pirkl , E. Heger , F. Incardona , A. Huefner , S. Jordan , S. Schmiedel , A. Fathi , R. Kaiser , O. Degen University Medical Center Hamburg-Eppendorf, Infectious Diseases Clinic, Hamburg, Germany, Institut for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Institute of Virology, University Hospital Cologne, Cologne, Germany, CARE (Common Action against HIV/TB/HCV across the Regions of Europe), Rome, Italy, EuResist Network, Rome, Italy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Medical Department, Section Infectious Diseases & Tropical Medicine, Hamburg, Germany General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Ukraine has one of highest rates of HIV in Europe with an estimate of 240.000 adults being affected (1). Of those, 62% are aware of their status and only 57% receive ART (2). Data about HIV-resistance profiles in Ukraine is scare. Subtype distribution seems to be different from Western Europe and might be predominantly A6 (5). Characterization of HIV-1 is necessary for treatment optimization. Due to ongoing war Germany hosts 1 067 730 Ukrainian refugees (3). We aimed to analyze HIV-1 sequences from HIV-positive Ukrainian refugees who attended our ID-clinic in 2022. Method: We analyzed treatment data and HIV-sequences of 59 Ukrainian PLHIV. Clinical parameters were co-infections and prior ART. Viral load testing was performed from EDTA- blood. Sequencing was performed from plasma if VL was detectable or if suppressed from proviral DNA. Interpretation was performed with geno2pheno Tools (6). Results: 59 Ukrainian PLHIV were eligible. (66% female, median age 41 (24-61)). Median CD4 619/ml (12-1381/ml). 72% had suppressed VL. Only one patient was treatment naïve. 40 (75%) were on DTG-single tablet regime and 10 (17%) used Efavirenz. HCV antibodies were found in 18 of patients, 9 had detectable HCV VL. IGRA was positive in 14 patients (24%). Active TB was found in 2 individuals and one additional was diagnosed in Germany. Sequencing of HIV-1 was successful in 27 individuals (46%), in at least 22 Subtype A6 was documented. 20 (34%) had INSTI mutation L74I, only 2 had mutations E138 (0.3%). Conclusions: Our cohort had no patients on failing regimen. Predominant Subtype was A6. Combination of A6, integrase mutation L74I and NNRTI mutation E138K might impair therapies with long-acting cabotegravir/rilpivirine. It is important to guide patients with therapy and monitor on population level, if new virus variants expand in Germany among other patients’ groups with different background. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 2 3,4 3,4 3,4 5,4 1 1,6 1,6 1,6 3,4 1 1 2 3 4 5 6 159
RkJQdWJsaXNoZXIy Mzc2ODc=